147 related articles for article (PubMed ID: 25025012)
1. R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.
Lee HG; Choi Y; Kim SY; Kim I; Kim YK; Kim YS; Lee HS; Kim SJ; Kim JA; Park BB; Park J; Shim H; Eom HS; Lee J; Park SK; Cheong JW; Park KW
Blood Res; 2014 Jun; 49(2):107-14. PubMed ID: 25025012
[TBL] [Abstract][Full Text] [Related]
2. Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.
Lee HG; Kim SY; Kim I; Kim YK; Kim JA; Kim YS; Lee HS; Park J; Kim SJ; Shim H; Eom HS; Park BB; Lee J; Park SK; Cheong JW; Park KW
Blood Res; 2015 Sep; 50(3):160-6. PubMed ID: 26457283
[TBL] [Abstract][Full Text] [Related]
3. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
4. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
5. The significance of upfront autologous stem cell transplantation for high-intermediate/high-risk stage IV diffuse large B-cell lymphoma.
Koviazin AK; Filatova LV; Zyuzgin IS; Artemyeva AS; Poliatskin IL; Burda DS; Volchenkov SA; Elkhova SS; Semiglazova TY
Cancer Rep (Hoboken); 2023 Apr; 6(4):e1786. PubMed ID: 36855295
[TBL] [Abstract][Full Text] [Related]
6. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
7. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
8. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
Kagami Y; Yamamoto K; Shibata T; Tobinai K; Imaizumi Y; Uchida T; Shimada K; Minauchi K; Fukuhara N; Kobayashi H; Yamauchi N; Tsujimura H; Hangaishi A; Tominaga R; Suehiro Y; Yoshida S; Inoue Y; Suzuki S; Tokuhira M; Kusumoto S; Kuroda J; Yakushijin Y; Takamatsu Y; Kubota Y; Nosaka K; Morishima S; Nakamura S; Ogura M; Maruyama D; Hotta T; Morishima Y; Tsukasaki K; Nagai H
Cancer Sci; 2020 Oct; 111(10):3770-3779. PubMed ID: 32767806
[TBL] [Abstract][Full Text] [Related]
9. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
Epperla N; Hamadani M; Reljic T; Kharfan-Dabaja MA; Savani BN; Kumar A
Cancer; 2019 Dec; 125(24):4417-4425. PubMed ID: 31441943
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
11. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
12. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
[No Abstract] [Full Text] [Related]
14. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma.
Martelli M; Ferreri AJ; Agostinelli C; Di Rocco A; Pfreundschuh M; Pileri SA
Crit Rev Oncol Hematol; 2013 Aug; 87(2):146-71. PubMed ID: 23375551
[TBL] [Abstract][Full Text] [Related]
16. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
[TBL] [Abstract][Full Text] [Related]
17. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
18. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
[TBL] [Abstract][Full Text] [Related]
19. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients.
Zhao Y; Wang H; Jin S; Zheng J; Huang M; Tang Y; Jin Z; Qiu H; Tang X; Fu C; Han Y; Wu DP
Oncotarget; 2017 Sep; 8(42):73168-73176. PubMed ID: 29069860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
